Publication:
Young coconut juice, a potential therapeutic agent that could significantly reduce some pathologies associated with Alzheimer's disease: Novel findings

dc.contributor.authorNisaudah Radenahmaden_US
dc.contributor.authorFarid Salehen_US
dc.contributor.authorKitja Sawangjaroenen_US
dc.contributor.authorUraporn Vongvatcharanonen_US
dc.contributor.authorPatchara Subhadhirasakulen_US
dc.contributor.authorWilart Rundornen_US
dc.contributor.authorBoonsirm Withyachumnarnkulen_US
dc.contributor.authorJames R. Connoren_US
dc.contributor.otherPrince of Songkla Universityen_US
dc.contributor.otherHealth Sciences Center Kuwait Faculty of Medicineen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherPenn State College of Medicineen_US
dc.date.accessioned2018-05-03T08:34:16Z
dc.date.available2018-05-03T08:34:16Z
dc.date.issued2011-03-14en_US
dc.description.abstractBrains from ovariectomised (ovx) rats can display features similar to those observed in menopausal women with Alzheimer's disease (AD), and oestrogen seems to play a key role. Preliminary studies on young coconut juice (YCJ) have reported the presence of oestrogen-like components in it. The aim of the study was to investigate the effects of YCJ on the AD pathological changes in the brains of ovx rats. Rat groups included sham-operated, ovx, ovx+oestradiol benzoate (EB) and ovx+YCJ. Brain sections (4m) were taken and wer e immunostained with -amyloid (A) 1-42, glial fibrillary acidic protein (GFAP) (an intermediate neurofilament of astrocytes) and Tau-1 antibodies. A 1-42, GFAP and Tau-1 are considered as reliable biomarkers of amyloidosis, astrogliosis and tauopathy (neurofibrillary tangles), respectively, which in turn are characteristic features associated with AD. The serum oestradiol (E2) level was measured using a chemiluminescent immunoassay technique. YCJ restored the serum E2 to levels significantly (P < ·001) higher than that of the ovx group, and even that of the sham group. A deposition was significantly (P < ·0001) reduced in the cerebral cortex of the YCJ group, as compared with the ovx group and with the sham and ovx+EB groups (P < ·01). A similar trend was observed in relation to GFAP expression in the cerebral cortex and to Tau-1 expression in the hippocampus. This is a novel study demonstrating that YCJ could have positive future implications in the prevention and treatment of AD in menopausal women. © The Authors 2010.en_US
dc.identifier.citationBritish Journal of Nutrition. Vol.105, No.5 (2011), 738-746en_US
dc.identifier.doi10.1017/S0007114510004241en_US
dc.identifier.issn14752662en_US
dc.identifier.issn00071145en_US
dc.identifier.other2-s2.0-79953137074en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/12589
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79953137074&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectNursingen_US
dc.titleYoung coconut juice, a potential therapeutic agent that could significantly reduce some pathologies associated with Alzheimer's disease: Novel findingsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79953137074&origin=inwarden_US

Files

Collections